Sitemap

US pharma firm Moderna says its COVID-19 vaccine is 94.5% effective

More...

Diego Maradona: Argentina Legend Dies Aged 60

Football legend Diego Maradona, one of the...

Serbian Student Heads Second-Placed Team At Internet Innovation Competition

Mensa Serbia said on Tuesday that a...

EIB Supports Digitalisation Of Schools With €65 Million

Modern IT equipment and high-speed internet...

G20 Summit: G20 Leaders United To Address Major Global Pandemic And Economic Challenges

President of the European Commission, Ursula von der...

News

Diego Maradona: Argentina Legend Dies Aged 60

Football legend Diego Maradona, one of the greatest players of all time, has died at the age of 60. The...

Serbian Student Heads Second-Placed Team At Internet Innovation Competition

Mensa Serbia said on Tuesday that a Serbian doctoral candidate headed the team that won silver at the China...

EIB Supports Digitalisation Of Schools With €65 Million

Modern IT equipment and high-speed internet for primary and secondary schools across Serbia. 50 000 teachers to improve...

G20 Summit: G20 Leaders United To Address Major Global Pandemic And Economic Challenges

President of the European Commission, Ursula von der Leyen, and President of the European Council, Charles Michel, represented the EU at...

SSCC promotes the Serbian ICT market to Swiss companies

SSCC promotes the Serbian ICT market to Swiss companies in cooperation with Switzerland Global Enterprise. Switzerland Global Enterprise S-GE...

Moderna said that Phase 3 stage analysis suggested its coronavirus vaccine could prevent COVID-19. The news comes a week after Pfizer and German drug-maker BioNTech announced a vaccine of their own.

US pharmaceutical firm Moderna announced on Monday that early analysis of its COVID-19 vaccine suggested it was as much as 94.5% effective.

“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” said Stephane Bancel, Moderna’s CEO.

The news comes a week after Pfizer and their German partners BioNTech announced that their vaccine had reached 90% effectiveness. Russian researchers claimed similar success for its Sputnik V vaccine later that same day.

“Vaccines rely on observing natural infection in the community,” epidemiologist Eric Feigl-Ding told DW. “And then you can make conclusions. Infections are soaring across the world, and that actually allows you to see the effects much quicker.”

Coronavirus cases topped 11 million in the US over the weekend, with 1 million recorded in just the past week.

The pandemic has killed more than 1.3 million people worldwide, more than 245,000 of them in the U.S.

Moderna said it was confident it would receive emergency approval for its vaccine from US authorities in December.

Higher storage temperature

Both the Pfizer and Moderna vaccines are based on a new platform called messenger RNA, which is faster to produce than traditional vaccines.

Moderna’s vaccine was co-developed by the US National Institutes of Health and consists of two doses 28 days apart.

The company announced that its vaccine can remain stable at standard refrigerator temperatures of 2 degrees Celsius to 8 degrees Celsius (36 degrees Fahrenheit to 46 degrees Fahrenheit) for 30 days. Pfizer’s vaccine, on the other hand, needs to be stored in deep-freezer conditions which could complicate supply chain logistics.

EU: more vaccines coming

The European Commission said on Monday that Moderna’s announcement was encouraging and that the bloc was working to secure more supply deals with vaccine makers.

“More encouraging news from #COVID19 vaccine trials w/@moderna,” EU health commissioner Stella Kyriakides said on Twitter.

Source: deutsche welle

Related Articles

Government Passes New Anti-coronavirus Measures

The Serbian government adopted new measures to suppress the epidemic caused by the COVID-19 infectious disease, whose implementation will begin on 24 November 2020. The...

Coronavirus Vaccine: EU Seals Deal With BioNTech, Pfizer

The EU has greenlit a deal with the US and German firms to secure 300 million doses of their coronavirus vaccine for the bloc....

Oxford Covid Vaccine Works In All Ages, Trials Suggest

Covid vaccine being trialled by Oxford University and AstraZeneca offers hope for all age groups One of the world’s leading Covid-19 experimental vaccines produces an...

Coronavirus Digest: Europe Tightens Restrictions To Control Spread Of COVID-19

The Netherlands is going into a partial lockdown for at least four weeks. Meanwhile, Italy has imposed new restrictions on public gatherings, restaurants, sports...

Japan To Donate A Total Of 100 Million Yen To Serbia For COVID Fight

The Government of Japan will provide a total amount of 100 million yen (about 820,000 euros) to the Government of Serbia with the aim...

Italy Sends Serbia The Medical Team To Help Fight COVID19

The Italian Embassy in Belgrade announces that a six-member medical team has arrived in Serbia: two anesthesiologists, one emergency doctor, one specialist in infectious...

EU Supports Serbia’s Fight Against Coronavirus By Hiring 200 Medical Professionals

Doctor, nurses, administrative staff—some 200 medical professionals will be given employment as part of the European Union’s assistance in fighting coronavirus in Serbia. Head of...

59 New Cases Of Coronavirus Confirmed

The Ministry of Health announced today that samples of 5,470 people have been tested for coronavirus since the last report, of which 59 are...